Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

IRONVELD PLC Share Issue/Capital Change 2020

Apr 23, 2020

7719_sha_2020-04-23_491c4efe-4398-4222-a9b2-4ad7d429cdea.html

Share Issue/Capital Change

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

RNS Number : 6290K

Ironveld PLC

23 April 2020

Ironveld plc ("Ironveld" or the "Group")

Blocklisting Return

The Company gives below the information required by Schedule 6 of the AIM Rules for Companies in connection with the Ironveld plc Long Term Incentive Plan and EMI Share Option Scheme.

Name of applicant: Ironveld plc
Name of scheme: Ironveld plc Long Term Incentive Plan and EMI Share Option Scheme
Period of return: From: 23 October 2019 To: 22 April 2020
Balance under scheme from previous return: 910,761 Ordinary Shares
The amount by which the block scheme has been increased, if the scheme has been increased since the date of the last return: N/A
Number of securities issued/allotted under scheme during period: Nil
Balance under scheme not yet issued/allotted at end of period 910,761 Ordinary Shares
Number and class of securities originally listed and the date of admission 4,000,000 Ordinary Shares on 23 October 2013
Total number of securities in issue at the end of the period 654,990,841 Ordinary Shares
Name of contact: Martin Eales
Telephone number of contact: 020 7138 3204

For further information, please contact:

Ironveld plc

Giles Clarke, Chairman

Martin Eales, Chief Executive Officer
c/o Blytheweigh

+44 20 7138 3204
finnCap (Nomad and Broker)

Christopher Raggett / Hannah Boros
+44 20 7220 0500
Blytheweigh

Tim Blythe / Megan Ray
+44 20 7138 3204

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

BLRKKNBKOBKKOQB